GPP
ALLO icon

Great Point Partners’s Allogene Therapeutics ALLO Stock Holding History

Great Point Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-328,817
Closed -$12.4M – 35
2020
Q3 		$12.4M Buy
+328,817
New +$12.4M 1.12% 22

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Great Point Partners's ALLO Position: Q4 2020 in Review

Great Point Partners sold out of Allogene Therapeutics (ALLO) in Q4 2020, closing a stake of 328,817 shares — an estimated $12.4M sold.

Great Point Partners first reported a position in ALLO in Q3 2020 and held it in 1 quarter. The position peaked at $12.4M in Q3 2020. 165 funds tracked by Wall St. Rank hold ALLO as of Q4 2020.

  • Great Point Partners reported no remaining Allogene Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Great Point Partners sold 328,817 Allogene Therapeutics shares in Q4 2020, an estimated $12.4M.
  • Great Point Partners first reported a position in Allogene Therapeutics in Q3 2020 and held it in 1 quarter.
  • Great Point Partners's Allogene Therapeutics position peaked at $12.4M in Q3 2020.
  • 165 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2020.

Based on Great Point Partners's 13F filing for Q4 2020, filed 16 Feb 2021.